NanoBio receives NIAID contract for pandemic influenza vaccine adjuvant
The contract to develop a nanoemulsion adjuvant is initially worth $5.5 million, but the total contract could be worth up to $10.5 million if all options are exercised. The funding will support the research and development of NanoVax-Panflu, which combines a plant-based recombinant H5 pandemic influenza antigen with NanoBio's proprietary NE adjuvant. The vaccine could provide increased production by eliciting system and mucosal immunity.
"Our most recent studies at NanoBio have tested NE-adjuvanted vaccines for respiratory syncytial virus and type II genital herpes, two viruses that enter the body via mucosal sites," David Peralta, the CEO of NanoBio, said. "The results of these studies very clearly demonstrate the ability of the NE adjuvant to elicit mucosal immunity and the important role this type of immunity plays in protecting against disease."
The award includes a future option to test the NE adjuvant with an HIV vaccine. The combined adjuvant and vaccine could elicit mucosal immunity and minimize transmission of the deadly virus.
"With this contract support from NIAID, we will further our studies of the NE adjuvant and its important role in enhancing vaccines against challenging respiratory infections and sexually transmitted diseases," Peralta said. "We look forward to moving our NanoVax-Panflu vaccine towards the clinic and on the path to commercialization."
NanoBio's NanoStat technology platform uses oil-in-water nanoemulsion to incorporate, deliver and adjuvant multiple types of antigens.